Successful treatment of pemphigus vulgaris with etanercept in four patients

Journal of Drugs in Dermatology

Volumn 8, Issue 10, 2009, Pages 940-943

  Shetty, Anjali ^a   Marcum, Catherine B ^a   Glass, L Frank ^a   Carter, John D ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DOXYCYCLINE; ETANERCEPT; GOLD; IMMUNOGLOBULIN; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; GLUCOCORTICOID; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CASE REPORT; CHEEK MUCOSA; CONJUNCTIVA; DISEASE DURATION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FEMALE; GASTROINTESTINAL MUCOSA; GINGIVA; GINGIVITIS; HUMAN; MALE; MOUTH LESION; PEMPHIGUS VULGARIS; SOFT PALATE; VAGINA MUCOSA; DOSE RESPONSE; DRUG ANTAGONISM; HOSPITALIZATION; MIDDLE AGED; PEMPHIGUS; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PEMPHIGUS; PREDNISONE; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70350726494     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. D'Auria L, Bonifati C, Mussi A, et al. Cytokines in the sera of patients with pemphigus vulgaris: Interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity. Eur Cytokine Netw. 1997;8(4):8383-8387.
2. Lopez-Robles, E, Avalos-Diaz E, Vega-Memije E, et al. TNFα and IL-6 are mediators in the blistering process of pemphigus. Int J Dermatol. 2001;40(3):185-188. (Pubitemid 32586277)
3. Feliciani E, Toto P, Amerio P, et al. In vitro and in vivo expression of interleukin-1α and tumor necrosis factor-α mRNA in pemphigus vulgaris: Interleukin-1α and tumor necrosis factor-α are involved in acantholysis. J Invest Dermatol. 2000;114(1):71-77. (Pubitemid 30195975)
4. Feliciani C, Toto P, Amerio P. In vitro C3 mRNA expression in pemphigus vulgaris: complement activation is increased by IL-1α and TNF-α. J Cutan Med Surg. 1999;3(3):140-144. (Pubitemid 29056108)
5. Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor α antagonist etanercept. Cutis. 2004;74(4):245-247. (Pubitemid 39462890)
6. Lin M, Hsu C, Lee JY. Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol. 2005;141(6):680-682. (Pubitemid 41001066)
7. Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol. 2000;42(3):422-427. (Pubitemid 30470348)
8. Dupuy A, Vigyier M, Bedane C, et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol. 2004;140(1):91-96. (Pubitemid 38090275)
9. Morrison L. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol. 2004;51(5):817-819. (Pubitemid 39516904)
10. Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol. 2005;153:620-625. (Pubitemid 41248223)
11. Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2). J Am Acad Dermatol. 2007;56(1):e55-e79. (Pubitemid 44969298)
12. Goffe B, Cather JC. Etanercept: An overview. J Am Acad Dermatol. 2003;49(2 Suppl):S105-S111. (Pubitemid 36951254)
13. Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg. 2007;26(1):6-14. (Pubitemid 46349778)